Quantitative Analysis of SLC14A1 in Bladder Cancer

Data mining is described in the Supplementary materials. For the QuantiGene branched DNA assay and immunohistochemistry, the Institutional Review Board of Chi Mei Medical Center approved the retrospective retrieval (IRB10302015) of 42 and another 340 primary UTUCs, as well as 36 and another 295 UBUCs with available tissue blocks from patients who underwent surgical treatment with curative intent between 1996 and 2004, while samples from those who underwent palliative resection were excluded (Supplementary materials). To determine the clinical relevance of the SCL14A1 transcript level, 36 UBUCs and 42 UTUCs with normal, pTa-pT1 and pT2-pT4 specimens were evaluated. For immunohistochemistry, another 340 primary UTUCs and 295 UBUCs with available tissue blocks were used (Supplementary materials). One specific probe targeting the SLC14A1 transcript was designed for QuantiGene™ Sample Processing Kit, formalin-fixed paraffin-embedded (FFPE) samples (QS0107, ThermoFisher, USA) and QuantiGene™ Plex Assay Kit (QP1013, ThermoFisher) based on the user guides (Supplementary materials). Immunohistochemical (IHC) staining was performed on representative tissue sections cut from FFPE tissues at 4-µm thickness as in our previous study 14 (link) by probing specific anti-human antibodies (Supplementary materials).